Frekil
New accelerator entry · 2025-04-12 · the record
Today, it takes months to understand how drugs perform in the real world, delaying safety insights and leaving patients exposed to unknown risks and benefits for far too long. Frekil turns that months-long process into minutes, with full auditability and scientific rigor.
Frekil is a Y Combinator company in the Spring 2025 batch. Its directory entry describes it as: RWE Generation in minutes. The founders listed are Nikhil Tiwari (Founder/CEO), Shivesh Gupta (Founder/CTO) (Y Combinator directory entry, April 12, 2025).
Sell to companies like Frekil? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New accelerator entry · 2025-04-12 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Frekil.
Free to see. No signup.
More on Frekil and the records around it.
Get an email when Frekil changes status, grows its team or files a funding notice. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when Frekil raises, hires or launches. No email unless you switch it on.
Watch Frekil →Get the full cited report on Frekil
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Frekil: verified, sourced, every claim cited, ready in a few minutes. See pricing.
Saved here on this device in the meantime, so nothing is lost either way.
Today, it takes months to understand how drugs perform in the real world, delaying safety insights and leaving patients exposed to unknown risks and benefits for far too long. Frekil turns that months-long process into minutes, with full auditability and scientific rigor. Frekil accelerates real world evidence (RWE) generation for life sciences companies on their own clinical data from months to minutes. It connects to fragmented clinical data (EHR, Claims, etc.) and lets teams run end-to-end studies from study design, cohort extraction to SAP, statistical analysis, and final reports.
Founders, titles and bios as the company published them. Photographs are our own copies of the ones on that record, so they do not break when the original link expires.
No investor is drawn from a Form D — the form states how many invested and never who. The one investor on this graph is named because a batch has exactly one.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Frekil: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Frekil covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist FrekilYou get an alert in MentionFox the next time this company shows up.
If you're behind Frekil: acceptance into a YC batch is one of the few weeks a young company gets looked up by people who matter — investors, other founders, press. FoxPlug turns the commits, deploys, and releases you're already making into that story automatically, so anyone who looks finds something current. GetFoxChat puts a guide on your own site so the people YC's own page just sent you don't read one line and leave.
Sourced from the company's Y Combinator directory entry.
Each opens in a new tab, filled in for Frekil. With no account yet, you sign up free and land on the result.
Share the news. Sharing needs no account.

https://mentionfox.com/funding/yc-frekil